These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27042219)

  • 1. Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis.
    Fan M; Lin Y; Pan J; Yan W; Dai L; Shen L; Chen K
    Thorac Cancer; 2016 Mar; 7(2):173-81. PubMed ID: 27042219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer.
    Kranzfelder M; Schuster T; Geinitz H; Friess H; Büchler P
    Br J Surg; 2011 Jun; 98(6):768-83. PubMed ID: 21462364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades.
    Nishikawa G; Banik P; Thawani R; Kardosh A; Wood SG; Nabavizadeh N; Chen EY
    J Gastrointest Oncol; 2022 Jun; 13(3):1454-1466. PubMed ID: 35837173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients.
    Yuan M; Bao Y; Ma Z; Men Y; Wang Y; Hui Z
    Front Oncol; 2021; 11():628706. PubMed ID: 33777777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer--do we need another randomised trial?
    Hingorani M; Crosby T; Maraveyas A; Dixit S; Bateman A; Roy R
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):696-705. PubMed ID: 21684129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
    Gebski V; Burmeister B; Smithers BM; Foo K; Zalcberg J; Simes J;
    Lancet Oncol; 2007 Mar; 8(3):226-34. PubMed ID: 17329193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis.
    Ma HF; Lv GX; Cai ZF; Zhang DH
    Onco Targets Ther; 2018; 11():3441-3447. PubMed ID: 29942136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
    van der Woude SO; Hulshof MC; van Laarhoven HW
    Chin Clin Oncol; 2016 Feb; 5(1):13. PubMed ID: 26932437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials.
    Fu T; Bu ZD; Li ZY; Zhang LH; Wu XJ; Wu AW; Shan F; Ji X; Dong QS; Ji JF
    BMC Cancer; 2015 Apr; 15():322. PubMed ID: 25928286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis.
    Zheng B; Zheng W; Zhu Y; Lin XY; Xu BH; Chen C
    Chin Med J (Engl); 2013 Mar; 126(6):1178-82. PubMed ID: 23506601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy improves histological results compared with perioperative chemotherapy in locally advanced esophageal adenocarcinoma.
    Luc G; Vendrely V; Terrebonne E; Chiche L; Collet D
    Ann Surg Oncol; 2015 Feb; 22(2):604-9. PubMed ID: 25169119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis.
    Xu CP; Xue XJ; Liang N; Xu DG; Liu FJ; Yu XS; Zhang JD
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):549-59. PubMed ID: 24370686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
    Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis.
    Hong JC; Murphy JD; Wang SJ; Koong AC; Chang DT
    Ann Surg Oncol; 2013 Nov; 20(12):3999-4007. PubMed ID: 23800897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis.
    Schulze B; Bergis D; Balermpas P; Trojan J; Woeste G; Bechstein WO; Rödel C; Weiss C
    Oncol Lett; 2014 Feb; 7(2):534-540. PubMed ID: 24396483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of radiotherapy in the multimodal management of esophageal cancer.
    Fokas E; Weiss C; Rödel C
    Dig Dis; 2013; 31(1):30-7. PubMed ID: 23797120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
    Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
    Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.